Meeting
2020 Genitourinary Cancers Symposium
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.
Authors
Victor Moreno
START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain
Victor Moreno , Yohann Loriot , Begona Pérez Valderrama , Carmen Beato , Yann-Alexandre Vano , Mark T. Fleming , Ignacio Duran , Salvatore Siena , Jaszianne A. Tolbert , Anne OHagan , Sydney Akapame , Yvonne Y. Lau , Lionnel Geoffrois , Scott T. Tagawa , Begona Mellado , Arlene O. Siefker-Radtke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
2017-001980-19
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 511)
Abstract #
511
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.
First Author: Victor Moreno
Poster
2018 Genitourinary Cancers Symposium
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
First Author: Yohann Loriot
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium.
First Author: Arnold I. Chin
Poster
2022 ASCO Genitourinary Cancers Symposium
Interim results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium.
First Author: Arnold I. Chin